Keith A Cengel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/938151/publications.pdf

Version: 2024-02-01

110 6,559 27 79
papers citations h-index g-index

110 110 110 10364 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Adjuvant Photodynamic Therapy, Mediated via Topical Versus Systemic Administration of 5â€Aminolevulinic Acid for Control of Murine Mammary Tumor after Surgical Resection ⟨sup⟩â€⟨ sup⟩. Photochemistry and Photobiology, 2022, 98, 117-126.	1.3	1
2	Radiomic Phenotypes for Improving Early Prediction of Survival in Stage III Non-Small Cell Lung Cancer Adenocarcinoma after Chemoradiation. Cancers, 2022, 14, 700.	1.7	7
3	Forging Forward in Photodynamic Therapy. Cancer Research, 2022, 82, 534-536.	0.4	27
4	Real-time PDT dose dosimetry for pleural photodynamic therapy. , 2022, 11940, .		5
5	Transient expansion and myofibroblast conversion of adipogenic lineage precursors mediate bone marrow repair after radiation. JCI Insight, 2022, 7, .	2.3	7
6	Delayed-Phase Enhancement for Evaluation of Malignant Pleural Mesothelioma on Computed Tomography: A Prospective Cohort Study. Clinical Lung Cancer, 2021, 22, 210-217.e1.	1.1	10
7	Current delivery limitations of proton PBS for FLASH. Radiotherapy and Oncology, 2021, 155, 212-218.	0.3	35
8	Early Changes in Physical Activity and Quality of Life With Thoracic Radiation Therapy in Breast Cancer, Lung Cancer, and Lymphoma. International Journal of Radiation Oncology Biology Physics, 2021, 109, 946-952.	0.4	7
9	CT for detection of malignant posterior intercostal lymph nodes in patients undergoing pre-operative staging for malignant pleural mesothelioma. Lung Cancer, 2021, 152, 34-38.	0.9	1
10	Abstract IA-019: Preclinical studies with proton FLASH radiotherapy in mice and canines: Biological effects, biophysical considerations and potential mechanisms. , 2021, , .		0
11	Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial. Lung Cancer, 2021, 154, 5-12.	0.9	8
12	Could Protons Promote Tumor Control by Avoiding Lymphopenia?. Journal of Thoracic Oncology, 2021, 16, e39-e41.	0.5	2
13	Phase II Trial of Flaxseed to Prevent Acute Complications After Chemoradiation for Lung Cancer. Journal of Alternative and Complementary Medicine, 2021, 27, 824-831.	2.1	3
14	Characterization of a highâ€resolution 2D transmission ion chamber for independent validation of proton pencil beam scanning of conventional and FLASH dose delivery. Medical Physics, 2021, 48, 3948-3957.	1.6	16
15	Managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy. Lung Cancer, 2021, 157, 163-164.	0.9	4
16	FLASH Proton Radiotherapy Spares Normal Epithelial and Mesenchymal Tissues While Preserving Sarcoma Response. Cancer Research, 2021, 81, 4808-4821.	0.4	77
17	Multiblock Discriminant Analysis of Integrative 18F-FDG-PET/CT Radiomics for Predicting Circulating Tumor Cells in Early-Stage Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1451-1465.	0.4	9
18	Comparison of FLASH Proton Entrance and the Spread-Out Bragg Peak Dose Regions in the Sparing of Mouse Intestinal Crypts and in a Pancreatic Tumor Model. Cancers, 2021, 13, 4244.	1.7	48

#	Article	IF	CITATIONS
19	Evaluation of Light Fluence Distribution Using an IR Navigation System for HPPHâ€mediated Pleural Photodynamic Therapy (pPDT). Photochemistry and Photobiology, 2020, 96, 310-319.	1.3	16
20	Posterior Intercostal Lymph Nodes Double Recurrence and Death Risk in Malignant Pleural Mesothelioma. Annals of Thoracic Surgery, 2020, 110, 241-250.	0.7	5
21	Early Tumor and Nodal Response in Patients with Locally Advanced Non-Small Cell Lung Carcinoma Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2020, 106, 358-368.	0.4	6
22	Reactive Oxygen Species Explicit Dosimetry for Photofrinâ€mediated Pleural Photodynamic Therapy. Photochemistry and Photobiology, 2020, 96, 340-348.	1.3	15
23	In Memoriam Jarod C. Finlay, PhD. Photochemistry and Photobiology, 2020, 96, 218-218.	1.3	0
24	Updating Photon-Based Normal Tissue Complication Probability Models for Pneumonitis in Patients With Lung Cancer Treated With Proton Beam Therapy. Practical Radiation Oncology, 2020, 10, e330-e338.	1.1	4
25	Higher Dose Volumes May Be Better for Evaluating Radiation Pneumonitis in Lung Proton Therapy Patients Compared With Traditional Photon-Based Dose Constraints. Advances in Radiation Oncology, 2020, 5, 943-950.	0.6	6
26	Machine learning highlights the deficiency of conventional dosimetric constraints for prevention of high-grade radiation esophagitis in non-small cell lung cancer treated with chemoradiation. Clinical and Translational Radiation Oncology, 2020, 22, 69-75.	0.9	9
27	Gender-based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma. Clinical Lung Cancer, 2020, 21, e583-e591.	1.1	11
28	In vivo Spectroscopic Evaluation of the Intraperitoneal Cavity in Canines. Photochemistry and Photobiology, 2020, 96, 426-433.	1.3	3
29	Preclinical Evaluation of Cetuximab and Benzoporphyrin Derivativeâ€Mediated Intraperitoneal Photodynamic Therapy in a Canine Model. Photochemistry and Photobiology, 2020, 96, 684-691.	1.3	7
30	Blood Flow Measurements Enable Optimization of Light Delivery for Personalized Photodynamic Therapy. Cancers, 2020, 12, 1584.	1.7	8
31	Proton-Beam Therapy: At the Heart of Cardiac Dose-Sparing in Mediastinal Radiotherapy for Thymic Carcinoma. Journal of Thoracic Oncology, 2020, 15, 1240-1242.	0.5	5
32	Photodynamic Therapy and Immune Checkpoint Blockade ^{â€} . Photochemistry and Photobiology, 2020, 96, 954-961.	1.3	54
33	Infrared navigation system for light dosimetry during pleural photodynamic therapy. Physics in Medicine and Biology, 2020, 65, 075006.	1.6	16
34	Light Fluence Rate and Tissue Oxygenation (S _t O ₂) Distributions Within the Thoracic Cavity of Patients Receiving Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma. Photochemistry and Photobiology, 2020, 96, 417-425.	1.3	5
35	Design, Implementation, and inÂVivo Validation of a Novel Proton FLASH Radiation Therapy System. International Journal of Radiation Oncology Biology Physics, 2020, 106, 440-448.	0.4	274
36	Circulating Tumor Cells Are Associated with Recurrent Disease in Patients with Early-Stage Nonâ€"Small Cell Lung Cancer Treated with Stereotactic Body Radiotherapy. Clinical Cancer Research, 2020, 26, 2372-2380.	3.2	41

#	Article	IF	CITATIONS
37	CLO20-030: Sex-Based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, CLO20-030.	2.3	O
38	Initial Clinical Experience Treating Patients With Lung Cancer on a 6MV-Flattening-Filter-Free O-Ring Linear Accelerator. Cureus, 2020, 12, e10325.	0.2	1
39	Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes. Oncolmmunology, 2019, 8, e1638211.	2.1	33
40	Predicting radiation pneumonitis in locally advanced stage II–III non-small cell lung cancer using machine learning. Radiotherapy and Oncology, 2019, 133, 106-112.	0.3	66
41	Early Detection of Recurrence in Patients With Locally Advanced Non–Small-Cell Lung Cancer via Circulating Tumor Cell Analysis. Clinical Lung Cancer, 2019, 20, 384-390.e2.	1.1	20
42	Design and commissioning of an image-guided small animal radiation platform and quality assurance protocol for integrated proton and x-ray radiobiology research. Physics in Medicine and Biology, 2019, 64, 135013.	1.6	22
43	Lymphangitic carcinomatosis: A common radiographic manifestation of local failure following extended pleurectomy/decortication in patients with malignant pleural mesothelioma. Lung Cancer, 2019, 132, 94-98.	0.9	3
44	A Clinical Trial of TumorGlow to Identify Residual Disease During Pleurectomy and Decortication. Annals of Thoracic Surgery, 2019, 107, 224-232.	0.7	18
45	A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma. Photochemistry and Photobiology, 2019, 95, 411-418.	1.3	19
46	Luminol Chemiluminescence Reports Photodynamic Therapyâ€Generated Neutrophil Activity <i>In Vivo</i> and Serves as a Biomarker of Therapeutic Efficacy. Photochemistry and Photobiology, 2019, 95, 430-438.	1.3	20
47	Modeling Epidermal Growth Factor Inhibitorâ€mediated Enhancement of Photodynamic Therapy Efficacy Using 3D Mesothelioma Cell Culture. Photochemistry and Photobiology, 2019, 95, 397-405.	1.3	6
48	Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non–small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location. Clinical Lung Cancer, 2019, 20, e63-e71.	1.1	36
49	First-ever Abscopal Effect after Palliative Radiotherapy and Immuno-gene Therapy for Malignant Pleural Mesothelioma. Cureus, 2019, 11, e4102.	0.2	17
50	Limitations in predicting the space radiation health risk for exploration astronauts. Npj Microgravity, 2018, 4, 8.	1.9	131
51	The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Before Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung Cancer. Clinical Lung Cancer, 2018, 19, e205-e209.	1.1	3
52	Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiationâ€induced osteoporosis. FASEB Journal, 2018, 32, 52-62.	0.2	26
53	Lesion oxygenation associates with clinical outcomes in premalignant and early stage head and neck tumors treated on a phase 1 trial of photodynamic therapy. Photodiagnosis and Photodynamic Therapy, 2018, 21, 28-35.	1.3	30
54	PDT dose dosimetry for Photofrin-mediated pleural photodynamic therapy (pPDT). Physics in Medicine and Biology, 2018, 63, 015031.	1.6	31

#	Article	IF	Citations
55	Adjuvant, neoadjuvant, and definitive radiation therapy for malignant pleural mesothelioma. Journal of Thoracic Disease, 2018, 10, S2565-S2573.	0.6	18
56	Circulating Tumor Cell Assessment in Presumed Early Stage Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Prospective Pilot Study. International Journal of Radiation Oncology Biology Physics, 2018, 102, 536-542.	0.4	21
57	A preclinical model to investigate the role of surgicallyâ€induced inflammation in tumor responses to intraoperative photodynamic therapy. Lasers in Surgery and Medicine, 2018, 50, 440-450.	1.1	13
58	Determination of optical properties, drug concentration, and tissue oxygenation in human pleural tissue before and after Photofrin-mediated photodynamic therapy. , 2018, 10476, .		0
59	A Comparison of Dose Metrics to Predict Local Tumor Control for Photofrinâ€mediated Photodynamic Therapy. Photochemistry and Photobiology, 2017, 93, 1115-1122.	1.3	22
60	A summary of light dose distribution using an IR navigation system for Photofrin-mediated Pleural PDT. Proceedings of SPIE, 2017, 10047, .	0.8	6
61	Extended Pleurectomy-Decortication–Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years. Annals of Thoracic Surgery, 2017, 103, 912-919.	0.7	103
62	Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms. Journal of Bone and Mineral Research, 2017, 32, 360-372.	3.1	88
63	The value of delayed phase enhanced imaging in malignant pleural mesothelioma. Journal of Thoracic Disease, 2017, 9, 2344-2349.	0.6	18
64	Radiotherapy and Photodynamic Therapy for Malignant Pleural Mesothelioma. Current Cancer Research, 2017, , 295-311.	0.2	3
65	PDT: What's Past Is Prologue. Cancer Research, 2016, 76, 2497-2499.	0.4	31
66	Toxicities and early outcomes in a phase 1 trial of photodynamic therapy for premalignant and early stage head and neck tumors. Oral Oncology, 2016, 55, 37-42.	0.8	27
67	Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy. Clinical Cancer Research, 2016, 22, 3791-3800.	3.2	77
68	Fluorinated Photodynamic Therapy Device Tips and their Resistance to Fouling for In Vivo Sensitizer Release. Photochemistry and Photobiology, 2016, 92, 166-172.	1.3	8
69	Measuring the Physiologic Properties of Oral Lesions Receiving Fractionated Photodynamic Therapy. Photochemistry and Photobiology, 2015, 91, 1210-1218.	1.3	18
70	An IR navigation system for pleural PDT. Frontiers in Physics, 2015, 3, .	1.0	18
71	Erlotinib Pretreatment Improves Photodynamic Therapy of Non–Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms. Cancer Research, 2015, 75, 3118-3126.	0.4	41
72	Real-time treatment light dose guidance of Pleural PDT: an update. Proceedings of SPIE, 2015, 9308, .	0.8	9

#	Article	IF	Citations
73	PTH1–34 Blocks Radiation-induced Osteoblast Apoptosis by Enhancing DNA Repair through Canonical Wnt Pathway. Journal of Biological Chemistry, 2015, 290, 157-167.	1.6	51
74	Dermatopathology effects of simulated solar particle event radiation exposure in the porcine model. Life Sciences in Space Research, 2015, 6, 21-28.	1.2	10
75	lonizing Radiation Selectively Reduces Skin Regulatory T Cells and Alters Immune Function. PLoS ONE, 2014, 9, e100800.	1.1	12
76	Determination of tissue optical properties in PDT treated head and neck patients. Proceedings of SPIE, 2014, 8926, .	0.8	6
77	Photodynamic Therapy for Lung Cancer and Malignant Pleural Mesothelioma. Seminars in Oncology, 2014, 41, 820-830.	0.8	88
78	Pencil beam scanning dosimetry for large animal irradiation. Journal of Radiation Research, 2014, 55, 855-861.	0.8	0
79	Acute hematological effects in mice exposed to the expected doses, dose-rates, and energies of solar particle event-like proton radiation. Life Sciences in Space Research, 2014, 2, 86-91.	1.2	29
80	Perineural spread of malignant mesothelioma with spinal intramedullary involvement. Clinical Neurology and Neurosurgery, 2014, 120, 116-119.	0.6	5
81	PTH1–34 alleviates radiotherapy-induced local bone loss by improving osteoblast and osteocyte survival. Bone, 2014, 67, 33-40.	1.4	77
82	In Regard to Tang etÂal. International Journal of Radiation Oncology Biology Physics, 2014, 90, 240.	0.4	0
83	Definitive surgery and intraoperative photodynamic therapy: A prospective study of local control and survival for patients with pleural dissemination of non-small cell lung cancer., 2014, 8931,.		3
84	Real-time treatment feedback guidance of Pleural PDT. , 2013, 8568, .		8
85	Dietary Flaxseed in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation. Journal of Pulmonary & Respiratory Medicine, 2013, 03, 154.	0.1	2
86	Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3. Cancer Biology and Therapy, 2012, 13, 1463-1470.	1.5	44
87	A real-time treatment guidance system for pleural PDT. Proceedings of SPIE, 2012, 8210, .	0.8	5
88	Adapting Preclinical Concepts for Use in Clinical Trials of Serosal and Interstitial Photodynamic Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, S-18-S-22.	2.3	1
89	Radical Pleurectomy and Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma. Annals of Thoracic Surgery, 2012, 93, 1658-1667.	0.7	132
90	Photodynamic therapy of cancer: An update. Ca-A Cancer Journal for Clinicians, 2011, 61, 250-281.	157.7	3,902

#	Article	IF	Citations
91	Photodynamic Therapy and the Evolution of a Lung-Sparing Surgical Treatment for Mesothelioma. Annals of Thoracic Surgery, 2011, 91, 1738-1745.	0.7	61
92	An IR navigation system for real-time treatment guidance of pleural PDT. Proceedings of SPIE, 2011, 7886, .	0.8	11
93	Flaxseed Lignan Complex (FLC) Enriched in Secoisolariciresinol Diglucoside (SDG) Prolongs Survival And Protects Against Radiationâ€induced Pneumonopathy In Mice. FASEB Journal, 2011, 25, 106.5.	0.2	0
94	Using electron beam radiation to simulate the dose distribution for whole body solar particle event proton exposure. Radiation and Environmental Biophysics, 2010, 49, 715-721.	0.6	26
95	Pleural Malignancies. Seminars in Radiation Oncology, 2010, 20, 208-214.	1.0	12
96	In vivo light dosimetry for HPPH-mediated pleural PDT. Proceedings of SPIE, 2010, 7551, .	0.8	9
97	Spectroscopic evaluation of photodynamic therapy of the intraperitoneal cavity. , 2010, 7551, .		1
98	A heterogeneous optimization algorithm for reacted singlet oxygen for interstitial PDT., 2010, 7551, .		2
99	In vivo light dosimetry for pleural PDT. , 2009, 7164, .		16
100	A heterogeneous algorithm for PDT dose optimization for prostate., 2009, 7164, 71640B.		3
101	Oncogenic K-Ras Signals through Epidermal Growth Factor Receptor and Wild-Type H-Ras to Promote Radiation Survival in Pancreatic and Colorectal Carcinoma Cells. Neoplasia, 2007, 9, 341-348.	2.3	82
102	Immunotherapy and radiation therapy for malignant pleural mesothelioma. Translational Lung Cancer Research, 2007, 6, 212-219.	1.3	31
103	Intraperitoneal Photodynamic Therapy. , 2007, 134, 493-514.		42
104	Dietary Flaxseed Prevents Fibrosis And Oxidative Lung Damage And Improves Mouse Survival In Experimental Thoracic Radiation Injury. FASEB Journal, 2007, 21, A172.	0.2	1
105	Dietary Flaxseed Reverses Radiationâ€Induced Alterations Of Gene Expression In Murine Lungs. FASEB Journal, 2007, 21, A61.	0.2	0
106	Radiosensitizing effects of the prenyltransferase inhibitor AZD3409 against RAS mutated cell lines Cancer Biology and Therapy, 2006, 5, 1206-1210.	1.5	11
107	Molecular targets for altering radiosensitivity: Lessons from Ras as a pre-clinical and clinical model. Critical Reviews in Oncology/Hematology, 2005, 55, 103-116.	2.0	20
108	C225 and PDT Combination Therapy for Ovarian Cancer: The Play's the Thing. Journal of the National Cancer Institute, 2005, 97, 1488-1489.	3.0	14

#	Article	lF	CITATIONS
109	Pancreatic Cancer Cell Radiation Survival and Prenyltransferase Inhibition: The Role of K-Ras. Cancer Research, 2005, 65, 8433-8441.	0.4	69
110	Effectiveness of the SurePath liquid-based Pap test in automated screening and in detection of HSIL. Diagnostic Cytopathology, 2003, 29, 250-255.	0.5	18